The effects of macronutrient intake on total and high-molecular weight adiponectin: Results from the OMNI-heart trial

Obesity

Volumn 18, Issue 8, 2010, Pages 1632-1637

  Yeung, Edwina H ^a   Appel, Lawrence J ^b,c,d   Miller, Edgar R ^b,c,d   Kao, W H Linda ^b,c,d  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MONOUNSATURATED FATTY ACID;

ADULT; ARTICLE; BLOOD; CALORIC INTAKE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET; FEMALE; HUMAN; MALE; MIDDLE AGED; NONPARAMETRIC TEST; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADIPONECTIN; ADULT; CHOLESTEROL, HDL; CROSS-OVER STUDIES; DIET; ENERGY INTAKE; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; STATISTICS, NONPARAMETRIC;

EID: 77955057901     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2009.402     Document Type: Article

References (29)

1. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005;26:439-451.
2. Choi KM, Lee J, Lee KW et al. The associations between plasma adiponectin, ghrelin levels and cardiovascular risk factors. Eur J Endocrinol 2004;150:715-718.
3. Hung J, McQuillan BM, Thompson PL, Beilby J P. Circulating adiponectin levels associate with inflammatory markers, insulin resistance and metabolic syndrome independent of obesity. Int J Obes (Lond) 2008;32:772-779.
4. Pischon T, Girman CJ, Rifai N, Hotamisligil GS, Rimm EB. Association between dietary factors and plasma adiponectin concentrations in men. Am J Clin Nutr 2005;81:780-786.
5. Esposito K, Pontillo A, Di Palo C et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003;289:1799-1804.
6. Krebs JD, Browning LM, McLean NK et al. Additive benefits of long-chain n-3 polyunsaturated fatty acids and weight-loss in the management of cardiovascular disease risk in overweight hyperinsulinaemic women. Int J Obes (Lond) 2006;30:1535-1544.
7. Kasim-Karakas SE, Tsodikov A, Singh U, Jialal I. Responses of inflammatory markers to a low-fat, high-carbohydrate diet: effects of energy intake. Am J Clin Nutr 2006;83:774-779.
8. Lithander FE, Keogh G F, Wang Y et al. No evidence of an effect of alterations in dietary fatty acids on fasting adiponectin over 3 weeks. Obesity (Silver Spring) 2008;16:592-599.
9. Paniagua JA, Gallego de la Sacristana A, Romero I et al. Monounsaturated fat-rich diet prevents central body fat distribution and decreases postprandial adiponectin expression induced by a carbohydrate-rich diet in insulin-resistant subjects. Diabetes Care 2007;30:1717-1723.
10. Aso Y, Yamamoto R, Wakabayashi S et al. Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes 2006;55:1954-1960.
11. Pajvani UB, Hawkins M, Combs TP et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004;279: 12152-12162.
12. Appel LJ, Sacks FM, Carey VJ et al.; OmniHeart Collaborative Research Group. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. JAMA 2005;294:2455-2464.
13. Carey VJ, Bishop L, Charleston J et al. Rationale and design of the Optimal Macro-Nutrient Intake Heart Trial to Prevent Heart Disease (OMNI-Heart). Clin Trials 2005;2:529-537.
14. Swain J F, McCarron PB, Hamilton E F, Sacks FM, Appel LJ. Characteristics of the diet patterns tested in the optimal macronutrient intake trial to prevent heart disease (OmniHeart): options for a heart-healthy diet. J Am Diet Assoc 2008;108:257-265.
15. Matthews DR, Hosker J P, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
17. Sinha MK, Songer T, Xiao Q et al. Analytical validation and biological evaluation of a high molecular-weight adiponectin ELISA. Clin Chem 2007;53:2144-2151.
18. Jones B, Kenward M. Design and Analysis of Cross-over Trials. Chapman & Hall/CRC: Washington, DC, 2003.
19. Ferré P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 2004;53(Suppl 1): S43-S50.
20. Warodomwichit D, Shen J, Arnett DK et al. ADIPOQ polymorphisms, monounsaturated fatty acids, and obesity risk: the GOLDN study. Obesity (Silver Spring) 2009;17:510-517.
21. Matsuura F, Oku H, Koseki M et al. Adiponectin accelerates reverse cholesterol transport by increasing high density lipoprotein assembly in the liver. Biochem Biophys Res Commun 2007;358:1091-1095.
22. Tiikkainen M, Häkkinen AM, Korsheninnikova E et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004;53:2169-2176.
23. Daimon M, Oizumi T, Saitoh T et al.; Funagata study. Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population: the Funagata study. Diabetes Care 2003;26:2015-2020.
24. Petersen KF, Dufour S, Savage DB et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci USA 2007;104:12587-12594.
25. Shand B, Elder P, Scott R, Frampton C, Willis J. Biovariability of plasma adiponectin. Clin Chem Lab Med 2006;44:1264-1268.
26. Beulens JW, van Beers RM, Stolk R P, Schaafsma G, Hendriks HF. The effect of moderate alcohol consumption on fat distribution and adipocytokines. Obesity (Silver Spring) 2006;14:60-66.
27. Beulens JW, de Zoete EC, Kok FJ, Schaafsma G, Hendriks HF. Effect of moderate alcohol consumption on adipokines and insulin sensitivity in lean and overweight men: a diet intervention study. Eur J Clin Nutr 2008;62:1098-1105.
28. Imhof A, Plamper I, Maier S, Trischler G, Koenig W. Effect of drinking on adiponectin in healthy men and women: a randomized intervention study of water, ethanol, red wine, and beer with or without alcohol. Diabetes Care 2009;32:1101-1103.
29. Kadowaki T, Yamauchi T, Kubota N. The physiological and pathophysiological role of adiponectin and adiponectin receptors in the peripheral tissues and CNS. FEBS Lett 2008;582:74-80.